Propensity-score-matched evaluation of the incidence of radiation pneumonitis and secondary cancer risk for breast cancer patients treated with IMRT/VMAT

被引:18
作者
Chao, Pei-Ju [1 ,2 ,3 ]
Lee, Hsiao-Fei [1 ,2 ,3 ]
Lan, Jen-Hong [1 ,2 ,3 ]
Guo, Shih-Sian [1 ,2 ,3 ]
Ting, Hui-Min [1 ,2 ,3 ]
Huang, Yu-Jie [2 ,3 ]
Chen, Hui-Chun [2 ,3 ]
Lee, Tsair-Fwu [1 ,2 ,3 ,4 ,5 ]
机构
[1] Natl Kaohsiung Univ Appl Sci, Med Phys & Informat Lab Elect Engn, Kaohsiung 80778, Taiwan
[2] Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, Kaohsiung 83342, Taiwan
[3] Chang Gung Univ, Coll Med, Kaohsiung 83342, Taiwan
[4] Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung 807, Taiwan
[5] Kaohsiung Yuans Gen Hosp, Dept Radiat Oncol, Kaohsiung 80249, Taiwan
关键词
MODULATED ARC THERAPY; HODGKINS-DISEASE; 2ND MALIGNANCY; RADIOTHERAPY; VMAT; SURVIVORS; IMRT; LUNG; FEASIBILITY; XEROSTOMIA;
D O I
10.1038/s41598-017-14145-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Propensity score matching evaluates the treatment incidence of radiation-induced pneumonitis (RP) and secondary cancer risk (SCR) after intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) for breast cancer patients. Of 32 patients treated with IMRT and 58 who received VMAT were propensity matched in a 1:1 ratio. RP and SCR were evaluated as the endpoints of acute and chronic toxicity, respectively. Self-fitted normal tissue complication probability (NTCP) parameter values were used to analyze the risk of RP. SCRs were evaluated using the preferred Schneider's parameterization risk models. The dosimetric parameter of the ipsilateral lung volume receiving 40 Gy (IV40) was selected as the dominant risk factor for the RP NTCP model. The results showed that the risks of RP and NTCP, as well as that of SCR of the ipsilateral lung, were slightly lower than the values in patients treated with VMAT versus IMRT (p <= 0.01). However, the organ equivalent dose and excess absolute risk values in the contralateral lung and breast were slightly higher with VMAT than with IMRT (p <= 0.05). When compared to IMRT, VMAT is a rational radiotherapy option for breast cancer patients, based on its reduced potential for inducing secondary malignancies and RP complications.
引用
收藏
页数:9
相关论文
共 36 条
[1]   Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancer [J].
Abo-Madyan, Yasser ;
Aziz, Muhammad Hammad ;
Aly, Moamen M. O. M. ;
Schneider, Frank ;
Sperk, Elena ;
Clausen, Sven ;
Giordano, Frank A. ;
Herskind, Carsten ;
Steil, Volker ;
Wenz, Frederik ;
Glatting, Gerhard .
RADIOTHERAPY AND ONCOLOGY, 2014, 110 (03) :471-476
[2]   LIMITED SMALL CELL LUNG-CANCER TREATED BY COMBINED RADIOTHERAPY AND CHEMOTHERAPY - EVALUATION OF A GRADING SYSTEM OF LUNG FIBROSIS [J].
ARRIAGADA, R ;
DEGUEVARA, JCL ;
MOURIESSE, H ;
HANZEN, C ;
COUANET, D ;
RUFFIE, P ;
BALDEYROU, P ;
DEWAR, J ;
LUSINCHI, A ;
MARTIN, M ;
LECHEVALIER, T .
RADIOTHERAPY AND ONCOLOGY, 1989, 14 (01) :1-8
[3]   A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality [J].
Austin, Peter C. .
MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (01) :119-151
[4]   Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples [J].
Austin, Peter C. .
STATISTICS IN MEDICINE, 2009, 28 (25) :3083-3107
[5]   Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years [J].
Dores, GM ;
Metayer, C ;
Curtis, RE ;
Lynch, CF ;
Clarke, EA ;
Glimelius, B ;
Storm, H ;
Pukkala, E ;
van Leeuwen, FE ;
Holowaty, EJ ;
Andersson, M ;
Wiklund, T ;
Joensuu, T ;
van't Veer, MB ;
Stovall, M ;
Gospodarowicz, M ;
Travis, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3484-3494
[6]   Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials [J].
Dowsett, M. ;
Forbes, J. F. ;
Bradley, R. ;
Ingle, J. ;
Aihara, T. ;
Bliss, J. ;
Boccardo, F. ;
Coates, A. ;
Coombes, R. C. ;
Cuzick, J. ;
Dubsky, P. ;
Gnant, M. ;
Kaufmann, M. ;
Kilburn, L. ;
Perrone, F. ;
Rea, D. ;
Thuerlimann, B. ;
van de Velde, C. ;
Pan, H. ;
Peto, R. ;
Davies, C. ;
Gray, R. ;
Baum, M. ;
Buzdar, A. ;
Sestak, I. ;
Markopoulos, C. ;
Fesl, C. ;
Jakesz, R. ;
Colleoni, M. ;
Gelber, R. ;
Regan, M. ;
von Minckwitz, G. ;
Snowdon, C. ;
Goss, P. ;
Pritchard, K. ;
Anderson, S. ;
Costantino, J. ;
Mamounas, E. ;
Ohashi, Y. ;
Watanabe, T. ;
Bastiaannet, E. .
LANCET, 2015, 386 (10001) :1341-1352
[7]   Propensity scores in intensive care and anaesthesiology literature: a systematic review [J].
Gayat, Etienne ;
Pirracchio, Romain ;
Resche-Rigon, Matthieu ;
Mebazaa, Alexandre ;
Mary, Jean-Yves ;
Porcher, Raphael .
INTENSIVE CARE MEDICINE, 2010, 36 (12) :1993-2003
[8]   Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer [J].
Golden, Daniel I. ;
Lipson, Jafi A. ;
Telli, Melinda L. ;
Ford, James M. ;
Rubin, Daniel L. .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2013, 20 (06) :1059-1066
[9]  
Hancock S. L., SEMIN RAD ONCOL, P225
[10]   US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status [J].
Howlader, Nadia ;
Altekruse, Sean F. ;
Li, Christopher I. ;
Chen, Vivien W. ;
Clarke, Christina A. ;
Ries, Lynn A. G. ;
Cronin, Kathleen A. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (05)